Harbor Capital Advisors Inc. Sells 2,957 Shares of Collegium Pharmaceutical, Inc. $COLL

Harbor Capital Advisors Inc. reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,884 shares of the specialty pharmaceutical company’s stock after selling 2,957 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of Collegium Pharmaceutical worth $529,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Collegium Pharmaceutical by 1.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after purchasing an additional 339 shares during the period. Millennium Management LLC increased its holdings in shares of Collegium Pharmaceutical by 38.8% during the fourth quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after purchasing an additional 51,972 shares during the period. ProShare Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 28.8% during the fourth quarter. ProShare Advisors LLC now owns 11,196 shares of the specialty pharmaceutical company’s stock worth $321,000 after purchasing an additional 2,506 shares during the period. State of Wyoming increased its holdings in shares of Collegium Pharmaceutical by 75.0% during the fourth quarter. State of Wyoming now owns 9,818 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 4,208 shares during the period. Finally, Vident Advisory LLC increased its holdings in shares of Collegium Pharmaceutical by 27.8% during the fourth quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock worth $484,000 after purchasing an additional 3,672 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. HC Wainwright raised shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $42.33.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $35.75 on Friday. The firm has a market cap of $1.13 billion, a PE ratio of 34.38 and a beta of 0.63. The firm’s fifty day moving average is $35.35 and its 200-day moving average is $31.17. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29.

Collegium Pharmaceutical declared that its board has initiated a stock repurchase plan on Monday, July 7th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 16,389 shares of Collegium Pharmaceutical stock in a transaction on Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at approximately $3,959,052.73. The trade was a 13.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Gordon Freund sold 11,659 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the transaction, the director owned 23,129 shares in the company, valued at approximately $794,712.44. The trade was a 33.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,792 shares of company stock worth $2,084,207 in the last three months. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.